Combination therapy with memin-KMT2A inhibitors and FLT3 inhibitors represents a promising strategy for AML with KMT2A-r or NPM1mt and concurrent FLT3 mutation (KMT2Ar/NPM1mt-FLT3mt). The gene discussed is KMT2A; the disease is acute myeloid leukemia.